Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Soticlestat Bioequivalence and Food Effect Study in Healthy Adults
NCT05284760Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of soticlestat in epilepsy (12 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration and 1 more. Started Mar 2022; status: completed.
02
Drugs
soticlestat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT05284760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05284760.